Another recent trial examined the efficacy and safety of enzalutamide with trastuzumab in patients with HER2+/AR+ locally advanced or metastatic BC in a single-arm phase II study in heavily pretreated patients with advanced HER2+ AR+ BC and observed a 24% CBR2439. Here, ERBB2 is linked to breast cancer.